Amgen Inc. $AMGN Stock Holdings Cut by Curated Wealth Partners LLC

Curated Wealth Partners LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 99.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,618 shares of the medical research company's stock after selling 433,767 shares during the quarter. Curated Wealth Partners LLC's holdings in Amgen were worth $682,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wellington Altus USA Inc. raised its holdings in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock valued at $28,000 after acquiring an additional 34 shares in the last quarter. Tower View Wealth Management LLC boosted its position in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Nvwm LLC boosted its position in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company's stock valued at $35,000 after acquiring an additional 66 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen in the second quarter valued at about $36,000. Finally, Evergreen Advisors LLC bought a new position in Amgen during the first quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AMGN shares. Oppenheimer reiterated an "outperform" rating on shares of Amgen in a research note on Wednesday, September 23rd. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their price target on Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a report on Thursday, August 6th. Wells Fargo & Company dropped their target price on shares of Amgen from $435.00 to $430.00 and set an "equal weight" rating for the company in a research note on Monday. Finally, BMO Capital Markets lowered their target price on Amgen from $450.00 to $415.00 and set a "market perform" rating for the company in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus price target of $387.93.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
• Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
• Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
• Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
• Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen

Amgen Stock Up 1.9%

AMGN stock opened at $434.03 on Friday. The business has a 50-day moving average of $415.11 and a 200-day moving average of $374.35. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03. The stock has a market capitalization of $234.65 billion, a P/E ratio of 26.98, a P/E/G ratio of 3.12 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the firm earned $6.02 earnings per share. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio (DPR) is currently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is owned by insiders.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.